Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hedin Charlotte Rose Hawkey, Sado Gina, Ndegwa Nelson, Lytvyak Ellina, Mason Andrew, Montano-Loza Aldo, Gerussi Alessio, Saffioti Francesca, Thorburn Douglas, Nilsson Emma, Larsson Geir, Moum Bjørn A, van Munster Kim N, Ponsioen Cyriel Y, Levy Cynthia, Nogueira Nicholas F, Bowlus Christopher L, Gotlieb Neta, Shibolet Oren, Lynch Kate D, Chapman Roger W, Rupp Christian, Vesterhus Mette, Jørgensen Kristin K, Rorsman Fredrik, Schramm Christoph, Sabino João, Vermeire Severine, Zago Alessandra, Cazzagon Nora, Marschall Hanns-Ulrich, Ytting Henriette, Ben Belkacem Karima, Chazouilleres Olivier, Almer Sven, International PSC Study Group, Bergquist Annika
Аннотация
METHODS: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy.
RESULTS: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P = .035). Factors associated with lower ALP were normal ALP at baseline (P < .01), treatment with adalimumab (P = .090), and treatment in Europe (P = .083).
CONCLUSIONS: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.